Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Transave, Inc.

Home Clinical Trial Sponsors and OrganizationsTransave, Inc.

Transave, Inc.

ACTIVE

11 Deerpark Dr Ste 117, 新泽西州米德尔塞克斯县, New Jersey, United Stateswww.transaveinc.comPrivate11–50 employeesEstablished: 1997-01-01

Part of transave llc

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

11

11 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

1997

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

4

36.4%

Trial Status Distribution

Active, not recruiting

11

100.0%

Clinical Trials

Trials sponsored by this organization (11)

A PLACEBO CONTROLLED, RANDOMIZED, PARALLEL COHORT, SAFETY AND TOLERABILITY STUDY OF TWO DOSE LEVELS OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN PATIENTS WITH BRONCHIECTASIS COMPLICATED BY CHRONIC INFECTION DUE TO PSEUDOMONAS AERUGINOSA

Active, not recruiting

Jul 200860 participants

A PLACEBO CONTROLLED, RANDOMIZED, PARALLEL COHORT, SAFETY AND TOLERABILITY STUDY OF TWO DOSE LEVELS OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN PATIENTS WITH BRONCHIECTASIS COMPLICATED BY CHRONIC INFECTION DUE TO PSEUDOMONAS AERUGINOSA

Active, not recruiting

Apr 200860 participants

A PLACEBO CONTROLLED, RANDOMIZED, PARALLEL COHORT, SAFETY AND TOLERABILITY STUDY OF TWO DOSE LEVELS OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN PATIENTS WITH BRONCHIECTASIS COMPLICATED BY CHRONIC INFECTION DUE TO PSEUDOMONAS AERUGINOSA

Active, not recruiting

Mar 200860 participants

A PLACEBO CONTROLLED, RANDOMIZED, PARALLEL COHORT, SAFETY AND TOLERABILITY STUDY OF TWO DOSE LEVELS OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN PATIENTS WITH BRONCHIECTASIS COMPLICATED BY CHRONIC INFECTION DUE TO PSEUDOMONAS AERUGINOSA

Active, not recruiting

Mar 200860 participants

A PLACEBO CONTROLLED, RANDOMIZED, PARALLEL COHORT, SAFETY AND TOLERABILITY STUDY OF TWO DOSE LEVELS OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN PATIENTS WITH BRONCHIECTASIS COMPLICATED BY CHRONIC INFECTION DUE TO PSEUDOMONAS AERUGINOSA

Active, not recruiting

Mar 200860 participants

MULTIDOSE SAFETY AND TOLERABILITY STUDY OF DOSE ESCALATION OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN CYSTIC FIBROSIS PATIENTS WITH CHRONIC INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA

Active, not recruiting

Aug 200760 participants

MULTIDOSE SAFETY AND TOLERABILITY STUDY OF DOSE ESCALATION OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN CYSTIC FIBROSIS PATIENTS WITH CHRONIC INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA

Active, not recruiting

Jul 200760 participants

MULTIDOSE SAFETY AND TOLERABILITY STUDY OF DOSE ESCALATION OF LIPOSOMAL AMIKACIN FOR INHALATION (ARIKACE™) IN CYSTIC FIBROSIS PATIENTS WITH CHRONIC INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA

Active, not recruiting

Apr 200760 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials11
Approvals
News

Back to Organizations